Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
empagliflozin + simvastatin
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**empagliflozin + simvastatin** is a combination of two small molecule drugs administered together for their respective therapeutic actions. - **Empagliflozin** is a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2) in the proximal tubule of the kidney. By blocking SGLT2, it decreases renal glucose reabsorption, resulting in increased urinary glucose excretion and improved glycemic control. It is primarily indicated for type 2 diabetes, with additional benefits in reducing cardiovascular mortality and managing chronic kidney disease[2][3][4]. - **Simvastatin** is an HMG-CoA reductase inhibitor (“statin”) that lowers cholesterol by inhibiting the rate-limiting enzyme in the cholesterol biosynthesis pathway, thus reducing total and LDL cholesterol and cardiovascular risk. - Co-administration of empagliflozin and simvastatin does not result in clinically relevant pharmacokinetic interactions, and no dose adjustments are needed when used together[1].
- Brand names
- GlyxambiSynjardyTrijardy
- Other names
- empagliflozin + simvastatin
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on empagliflozin + simvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on empagliflozin + simvastatin.